Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Acurx Pharmaceuticals, Inc. (ACXP) had Return on Tangible Equity of -151.21% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-7.97M |
|
-- |
|
-- |
|
$8.09M |
|
$-8.09M |
|
$0.13M |
|
$-7.97M |
|
$-7.97M |
|
$-7.97M |
|
$-7.97M |
|
$-7.97M |
|
$-7.97M |
|
$-8.09M |
|
$-8.09M |
|
1.50M |
|
1.50M |
|
$-5.32 |
|
$-5.32 |
|
| Balance Sheet Financials | |
$7.69M |
|
-- |
|
-- |
|
$7.69M |
|
$2.42M |
|
-- |
|
-- |
|
$2.42M |
|
$5.27M |
|
$5.27M |
|
$5.27M |
|
2.35M |
|
| Cash Flow Statement Financials | |
$-6.79M |
|
-- |
|
$10.64M |
|
$3.71M |
|
$7.56M |
|
$3.85M |
|
$1.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-151.21% |
|
|
Return on Tangible Equity |
-151.21% |
-103.60% |
|
-151.21% |
|
$2.24 |
|
$-4.53 |
|
$-4.53 |
|